anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
== Pathophysiology == Muscle atrophy occurs due to an imbalance between the normal balance between protein synthesis and protein degradation. This involves complex cell signalling that is incompletely understood and muscle atrophy is likely the result of multiple contributing mechanisms. Mitochondrial function is crucial to skeletal muscle health and detrimental changes at the level of the mitochondria may contribute to muscle atrophy. A decline in mitochondrial density as well as quality is consistently seen in muscle atrophy due to disuse. The ATP-dependent ubiquitin/proteasome pathway is one mechanism by which proteins are degraded in muscle. This involves specific proteins being tagged for destruction by a small peptide called ubiquitin which allows recognition by the proteasome to degrade the protein.
While EU law has not yet developed a civil code for contracts, torts, unjust enrichment, real or personal property, or commerce in general, European legal scholars have drafted common principles, including Principles of European Contract Law and Principles of European Tort Law that are common to member states. In absence of harmonisation, there is a comprehensive system of conflicts of laws to settle the jurisdiction of courts, and the applicable law, for most commercial disputes. The Brussels I Regulation 2012 determines the jurisdiction of courts depending upon where a person is domiciled or has operations. The applicable law for consensual obligations is then determined by the Rome I Regulation, where article 3 states the principle that a choice of law can be made expressly in a contract, unless this affects provisions that cannot be derogated from, such as employment, consumer, tenancy or other rights. The Rome II Regulation determines applicable law in the case of non-consensual obligations, such as torts and unjust enrichment. Under article 4 the general rule is that the law applies where "the damage occurred", although under article 7 in the case of "environmental damage or damage sustained by persons or property as a result" there is a choice to bring an action under the law of the tortfeasor. Unlike other property forms, intellectual property rights are comprehensively regulated by a series of directives on copyrights, patents and trademarks.
== Later life and FOP progression == Unaware of the consequences of surgery on an FOP patient, the physician admitted Eastlack for hip surgery in 1941 which caused further physical restriction. Over time Eastlack became more and more immobilized as more joints became fused and newly formed sheets or strings of bone calcified his limbs. In 1944, he was readmitted for a study which confirmed that the calcified smooth muscles, tendons, and ligaments had indeed become mature bone. The ossification along his vertebrae and other anatomical parts that Eastlack would suffer in the next 29 years ultimately fused him into a permanently bowed position. Eastlack's case of FOP progressed at a more rapid rate due to the number of intrusive surgeries he underwent. In 1948, at the age of 15, his jaw had become fused so he could no longer eat solid food and had to speak through clenched teeth. At a young age, he faced difficulty sitting down, as well. His hips were one of the first anatomical parts to become immobilized due to heterotopic ossification. Soon, bone formed across his upper arms and extended onto his sternum, tying his arms to his breast. Sheets of bone spread along his back and ribbons of bone extended from there to his skull, inhibiting proper head movement. The new bone growths throughout the years also caused juts of bone to form on his pelvis and thighs, and it caused both of his feet to become clubbed. One year he accidentally bumped his buttocks into a radiator, and this resulted in a bruise wherein the smooth tissue was destroyed and gave way to newly formed bone.
=== Human exposure === Human exposure varies across the globe and depends on factors such as smoking rates, fuel types in cooking, and pollution controls on power plants, industrial processes, and vehicles. Developed countries with stricter air and water pollution controls, cleaner sources of cooking (that is, gas and electricity versus coal or biofuels), and prohibitions of public smoking tend to have lower levels of PAH exposure, while developing and undeveloped countries tend to have higher levels. Surgical smoke plumes have been proven to contain PAHs in several independent research studies.
==== February ==== On 1 February, the Syrian government forces launched attacks toward Suwayda from the areas of Tal Hadid, Mansoura and Walgha, with four mortar shells. Clashes were reported between the National Guard and the Syrian government forces in the area of Mansour and the National Guard declared that it shot down a drone belonging to the Syrian government forces. A Syrian security source reported an attempted infiltration by what it called "outlaw gangs" in the area of Mansoura. On 2 February, the Syrian internal security forces arrested Nasser Faisal Al-Saadi, a member of the National Guard, Eagles of the Whirlwind and Hezbollah, in addition to being the "biggest drug dealer in the region". On 6 February, the Syrian government forces advanced towards the towns of Atil and Salim, reaching Sweida. A Syrian security source reported attacks toward al-Mazra'a. The Syrian government forces launched attacks toward al-Majdal with rocket launchers, killing the civilian Rani Basel Naeem. On 7 February, a Syrian internal security force member shot and killed four people in Al-Matouna, a rural area of Suwayda, and was later arrested by Syrian government forces. The civilians were harvesting olives before they were shot and had received a security clearance from the government to enter their land. On 10 February, the National Guard denied having closed the road between Umm al-Zaytoun and Damascus, declaring it as "misleading and false information" and that the crossing is controlled by Internal Security Forces in Suwayda.
Sources: en.wikipedia.org
Between her second and third flights, Caldwell Dyson continued to work inside Houston’s Mission Control Center as CAPCOM for both space shuttle and space station operations, serving as the lead CAPCOM for various ISS missions, including the lead and development of the CAPCOM cadre for Boeing Starliner Mission Operations team. She was also the ground IV for US EVA 32, performed by Scott Kelly and Kjell Lindgren. Caldwell Dyson initiated and led several projects to improve training and operations aboard the ISS, most notably developing the EVA Qualification training flow (EVQ) for astronaut candidates. After her third trip to space, she served as the ground IV for US EVA 95, performed by Jessica Meir and Christopher Williams in March 2026. She also worked as one of the CAPCOM for the Artemis II mission, working during 3 separate shifts. During the summer 2026 with the European Space Agency, she participated in the CAVES training program with her NASA astronaut colleague, Ben Bailey and astronauts from other agencies John McFall, Ayu Yoneda and Rosemary Coogan. As Tracy Dyson, she is the host of a series on NASA TV called StationLife, which focuses on facets of life aboard the International Space Station. On March 21, 2017, Caldwell Dyson stood behind President Trump as he signed a bill for NASA to send humans to Mars in the 2030s and receive $19.5 billion in 2018 funding. Caldwell Dyson and fellow NASA astronaut Chris Cassidy presented Trump with an official flight jacket during the ceremony.
== Research == Flunarizine may help to reduce the severity and duration of attacks of paralysis associated with the more serious form of alternating hemiplegia, as well as being effective in rapid onset dystonia-parkinsonism (RDP). Both these conditions arise from specific mutations in the ATP1A3 gene. Flunarizine extended motor neuron survival in spinal cord, protected skeletal muscles from cell death and atrophy and extended survival by 40% in an animal model of spinal muscular atrophy. Flunarizine has also shown promise as an anti-prion medication.
=== Board positions === As of 2024, Bhatt serves on the Board of Directors and Science and Technology Committee of Bristol Myers Squibb. He is on the cardiovascular advisory board for McKinsey and is a consultant to Broadview Ventures. He had previously served on the Board of Directors of the Boston VA Research Institute and as a Trustee of the American College of Cardiology. He is President of the Board of Directors of the American Heart Association New York City chapter.
== Tributes == "Referring to the death of Professor Brailsford Robertson yesterday, the Prime Minister (Mr. Scullin) said:— His untimely end has robbed Australia of a brilliant scientist, whose contribution to the Commonwealth's progress would always be remembered. On behalf of the Federal Ministry Mr. Scullin extended his sincere sympathy to Professor Robertson's family, and expressed its appreciation of the great national services which he had rendered." The Argus, 20 January 1930. "Professor Brailsford Robertson was one of Australia's most brilliant scientists. The value of the work he was accomplishing cannot be estimated." Hon. R.L. Butler, Premier of South Australia, 20 January 1930. "The main purpose of [Robertson's] studies was to solve the mystery of physical life in it successive stages of commencement, growth, decline, and cessation, for the benefit of his fellow-men. ... The amount of original work he accomplished in his short life was prodigious. I would be rash to assert that the loss to science, or as I should prefer to say, the loss to humanity, caused by his death is irreparable, but it will probably be a long time before anyone else is able to gather the threads together and produce the fabric he was attempting to weave on his loom." Sir George Murray, Chancellor of the University of Adelaide, 18 March 1932.
== Personal life == In 1971, Parsons married Gretchen Burrell (née Gretchen Lisl Berrill) at his stepfather's New Orleans estate. Parsons and Burrell went to England, where they visited their friend Ric Grech. With the help of Grech and his friend Hank Wangford, Parsons stopped using heroin. In the summer of 1973, Parsons' Topanga Canyon home burned to the ground, the result of a stray cigarette. Nearly all of his possessions were destroyed with the exception of a guitar and a prized Jaguar. The fire proved to be the last straw in the relationship between Burrell and Parsons, who moved into a spare room in Kaufman's house. Parsons rekindled his relationship with Margaret Fisher, a high school sweetheart from Waycross. Parsons had one child, born to Nancy Ross in 1967, Polly Parsons.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.